Upstream Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights
| UPB Stock | 16.44 0.68 3.97% |
About 56% of all Upstream Bio,'s investors are looking to take a long position. The analysis of overall sentiment of trading Upstream Bio, stock suggests that some investors are interested at this time. The current market sentiment, together with Upstream Bio,'s historical and current headlines, can help investors time the market. In addition, many technical investors use Upstream Bio, stock news signals to limit their universe of possible portfolio assets.
Upstream |
Advancing Phase 2 clinical trials of verekitug in patients with severe asthma and CRSwNP Commenced startup for a Phase 2 clinical trial in COPD on track for first patient to be dosed in H2 2025 Completed upsized IPO with gross proceeds of approximately 293 million, extending runway through 2027 WALTHAM, Mass., Nov. 07, 2024 -- Upstream Bio, Inc. , a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe
Read at finance.yahoo.com
 |
Upstream Bio, Fundamental Analysis
We analyze Upstream Bio,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Upstream Bio, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Upstream Bio, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
Upstream Bio, is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
Upstream Bio, Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Upstream Bio, stock to make a market-neutral strategy. Peer analysis of Upstream Bio, could also be used in its relative valuation, which is a method of valuing Upstream Bio, by comparing valuation metrics with similar companies.
Peers
Upstream Bio, Related Equities
| VIGL | Vigil Neuroscience | 11.11 | ||||
| VKTX | Viking Therapeutics | 1.18 | ||||
| VNDA | Vanda Pharmaceuticals | 0.21 | ||||
| VRCA | Verrica Pharmaceuticals | 0 | ||||
| VCNX | Vaccinex | 0.91 | ||||
| VRNA | Verona Pharma | 1.23 | ||||
| VRDN | Viridian Therapeutics | 1.89 | ||||
| DWTX | Dogwood Therapeutics, | 12.63 | ||||
| VIRX | Viracta Therapeutics | 33.33 |
Complementary Tools for Upstream Stock analysis
When running Upstream Bio,'s price analysis, check to measure Upstream Bio,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Upstream Bio, is operating at the current time. Most of Upstream Bio,'s value examination focuses on studying past and present price action to predict the probability of Upstream Bio,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Upstream Bio,'s price. Additionally, you may evaluate how the addition of Upstream Bio, to your portfolios can decrease your overall portfolio volatility.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |